| SEC For | m 4 | | | | | | | | | | | | | | | | |
|---|---|--|---|---|--|----------------------------------|-----------|------|--|--------------------|---|--|--|--|---|--|--|
| FORM 4 UNITED | | | | D STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | | | | OMB APPROVAL | | |
| Section obligat | this box if no lo 16. Form 4 or ions may contin tion 1(b). | | STAT | | d purs | TOF CHANGES IN BENEFICIAL OWNERS | | | | | | | | HP OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | | | |
| 1. Name and Address of Reporting Person [*] Gross Jane A (Last) (First) (Middle) C/O APTEVO THERAPEUTICS INC. | | | | | 2. Issuer Name and Ticker or Trading Symbol <u>Aptevo Therapeutics Inc.</u> [APVO] 3. Date of Earliest Transaction (Month/Day/Year) 01/29/2021 | | | | | | | | Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner X Officer (give title below) SVP & Chief Scientific Officer | | | | |
| 2401 4TH AVENUE, SUITE 1050 (Street) SEATTLE WA 98121 (City) (State) (Zip) | | | | | 4. 1 | Line) X Form file | | | | | | | | loint/Group Filing (Check Applicable iled by One Reporting Person iled by More than One Reporting | | | |
| | | Tab | le I - Nor | n-Deriv | ative | e Se | curities | s Ac | quired, Di | sposed o | of, or Be | neficial | ly Owned | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | | | Execution Date, | | | r) Transaction Disposed Code (Instr. 5) 8) | | ties Acquired (A) or d Of (D) (Instr. 3, 4 and (A) or Deice | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(c) | | Form: Direct (D) or Indirect | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | | | | | | | (Instr. 3 a | Transaction(s) (Instr. 3 and 4) wned | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | | 4. Transaction Code (Instr. 8) | | 5. Number | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | Ownership Form: y Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | |
| Stock Option (right to buy) | \$33.5 | 01/29/2021 | | | Α | | 16,500 | | (1) | 01/29/2031 | Common Stock | 16,500 | \$0 | 16,500 | D | | |
| Restricted Stock Unit | (2) | 01/29/2021 | | | A | | 5,500 | | (3) | (3) | Common Stock | 5,500 | \$0 | 5,500 | D | | |

Explanation of Responses:

1. The option vests in three approximately equal annual installments beginning on January 29, 2022.

2. Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis.

3. The RSU vests in three approximately equal annual installments beginning on January 29, 2022.

<u>/s/ Carl A. Valenstein, attorney-</u> 02/17/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.